{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:06:05Z","timestamp":1788930365529,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40262-025-01477-5","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T14:07:45Z","timestamp":1746108465000},"page":"791-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Scoping Review of Paediatric Population Pharmacokinetic Models of Morphine"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6615-4998","authenticated-orcid":false,"given":"Michael A.","family":"Stokes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-9555","authenticated-orcid":false,"given":"Noha A.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-7841","authenticated-orcid":false,"given":"Marino S.","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-8262","authenticated-orcid":false,"given":"Indy","family":"Sandaradura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"issue":"4","key":"1477_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2125.1989.tb05399.x","volume":"27","author":"PJ Hoskin","year":"1989","unstructured":"Hoskin PJ, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol. 1989;27(4):499\u2013505.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1477_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/J354v16n04_02","volume":"16","author":"RA Lugo","year":"2002","unstructured":"Lugo RA, Kern SE. Clinical pharmacokinetics of morphine. J Pain Palliat Care Pharmacother. 2002;16(4):5\u201318.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"1477_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0885-3924(02)00531-6","volume":"25","author":"G Andersen","year":"2003","unstructured":"Andersen G, Christrup L, Sj\u00f8gren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manag. 2003;25(1):74\u201391.","journal-title":"J Pain Symptom Manag"},{"key":"1477_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.882443","volume":"15","author":"F Gabel","year":"2022","unstructured":"Gabel F, et al. Morphine-3-glucuronide, physiology and behavior. Front Mol Neurosci. 2022;15: 882443.","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"1477_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/bja\/aeu186","volume":"113","author":"R Klimas","year":"2014","unstructured":"Klimas R, Mikus G. Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth. 2014;113(6):935\u201344.","journal-title":"Br J Anaesth"},{"issue":"1","key":"1477_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s44158-022-00036-9","volume":"2","author":"A Amigoni","year":"2022","unstructured":"Amigoni A, et al. Recommendations for analgesia and sedation in critically ill children admitted to intensive care unit. J Anesth Analg Crit Care. 2022;2(1):9.","journal-title":"J Anesth Analg Crit Care."},{"issue":"5","key":"1477_CR7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00431-023-04905-5","volume":"182","author":"MC Mondardini","year":"2023","unstructured":"Mondardini MC, et al. Analgesia and sedation in critically ill pediatric patients: an update from the recent guidelines and point of view. Eur J Pediatrics. 2023;182(5):2013\u201326.","journal-title":"Eur J Pediatrics."},{"key":"1477_CR8","doi-asserted-by":"crossref","unstructured":"Di Nardo M, Wildschut ED. Drugs pharmacokinetics during veno-venous extracorporeal membrane oxygenation in pediatrics. J Thoracic Dis. 2017: S642-S652.","DOI":"10.21037\/jtd.2017.11.02"},{"issue":"1","key":"1477_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0304-3959(97)00142-5","volume":"74","author":"CC Faura","year":"1998","unstructured":"Faura CC, et al. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain. 1998;74(1):43\u201353.","journal-title":"Pain"},{"issue":"11","key":"1477_CR10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/jcm11113009","volume":"11","author":"JD Morse","year":"2022","unstructured":"Morse JD, Cortinez LI, Anderson BJ. Pharmacokinetic pharmacodynamic modelling contributions to improve paediatric anaesthesia practice. J Clin Med. 2022;11(11):3009.","journal-title":"J Clin Med"},{"issue":"5","key":"1477_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1093\/bja\/aeg121","volume":"90","author":"NJ Bouwmeester","year":"2003","unstructured":"Bouwmeester NJ, et al. Age- and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. Br J Anaesth. 2003;90(5):642\u201352.","journal-title":"Br J Anaesth"},{"issue":"1","key":"1477_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1460-9592.2012.03917.x","volume":"23","author":"J Taylor","year":"2013","unstructured":"Taylor J, Liley A, Anderson BJ. The relationship between age and morphine infusion rate in children. Pediatr Anesth. 2013;23(1):40\u20134.","journal-title":"Pediatr Anesth"},{"issue":"9","key":"1477_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/jcph.1620","volume":"60","author":"AJ Valkenburg","year":"2020","unstructured":"Valkenburg AJ, et al. Exploring the relationship between morphine concentration and oversedation in children after cardiac surgery. J Clin Pharmacol. 2020;60(9):1231\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1477_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3959(84)90878-9","volume":"18","author":"MC Nahata","year":"1984","unstructured":"Nahata MC, et al. Analgesic plasma concentrations of morphine in children with terminal malignancy receiving a continuous subcutaneous infusion of morphine sulfate to control severe pain. Pain. 1984;18(2):109\u201314.","journal-title":"Pain"},{"issue":"3","key":"1477_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/cpt1979263354","volume":"26","author":"B Dahlstr\u00f6m","year":"1979","unstructured":"Dahlstr\u00f6m B, et al. Morphine kinetics in children. Clin Pharmacol Ther. 1979;26(3):354\u201365.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1477_CR16","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40262-016-0398-z","volume":"55","author":"MH Elkomy","year":"2016","unstructured":"Elkomy MH, et al. Pharmacodynamic analysis of morphine time-to-remedication events in infants and young children after congenital heart surgery. Clin Pharmacokinet. 2016;55(10):1217\u201326.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1477_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.6061\/clinics\/2016(08)11","volume":"71","author":"GM Pacifici","year":"2016","unstructured":"Pacifici GM. Metabolism and pharmacokinetics of morphine in neonates: a review. Clinics (Sao Paulo). 2016;71(8):474\u201380.","journal-title":"Clinics (Sao Paulo)"},{"issue":"10","key":"1477_CR18","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","volume":"18","author":"MDJ Peters","year":"2020","unstructured":"Peters MDJ, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119\u201326.","journal-title":"JBI Evid Synth."},{"issue":"7","key":"1477_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40261-013-0097-6","volume":"33","author":"C Wang","year":"2013","unstructured":"Wang C, et al. Developmental changes in morphine clearance across the entire paediatric age range are best described by a bodyweight-dependent exponent model. Clin Drug Invest. 2013;33(7):523\u201334.","journal-title":"Clin Drug Invest"},{"issue":"3","key":"1477_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1460-9592.2011.03782.x","volume":"22","author":"NHG Holford","year":"2012","unstructured":"Holford NHG, Ma SC, Anderson BJ. Prediction of morphine dose in humans. Pediatr Anesth. 2012;22(3):209\u201322.","journal-title":"Pediatr Anesth"},{"issue":"1","key":"1477_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jcph.775","volume":"57","author":"A Frymoyer","year":"2017","unstructured":"Frymoyer A, et al. Decreased morphine clearance in neonates with hypoxic ischemic encephalopathy receiving hypothermia. J Clin Pharmacol. 2017;57(1):64\u201376.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1477_CR22","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/cpt.1917","volume":"108","author":"LMA Favi\u00e9","year":"2020","unstructured":"Favi\u00e9 LMA, et al. Prediction of drug exposure in critically ill encephalopathic neonates treated with therapeutic hypothermia based on a pooled population pharmacokinetic analysis of seven drugs and five metabolites. Clin Pharmacol Therap. 2020;108(5):1098\u2013106.","journal-title":"Clin Pharmacol Therap."},{"issue":"2","key":"1477_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211910","volume":"14","author":"LMA Favi\u00e9","year":"2019","unstructured":"Favi\u00e9 LMA, et al. Pharmacokinetics of morphine in encephalopathic neonates treated with therapeutic hypothermia. PLoS One. 2019;14(2): e0211910.","journal-title":"PLoS One"},{"issue":"7","key":"1477_CR24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2165\/00003088-200645070-00005","volume":"45","author":"JWB Peters","year":"2006","unstructured":"Peters JWB, et al. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet. 2006;45(7):705\u201314.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1477_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00134-004-2545-5","volume":"31","author":"JWB Peters","year":"2005","unstructured":"Peters JWB, et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intens Care Med. 2005;31(2):257\u201363.","journal-title":"Intens Care Med."},{"issue":"10","key":"1477_CR26","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1097\/PCC.0000000000000904","volume":"17","author":"AJ Valkenburg","year":"2016","unstructured":"Valkenburg AJ, et al. Pharmacodynamics and pharmacokinetics of morphine after cardiac surgery in children with and without Down syndrome. Pediatr Crit Care Med. 2016;17(10):930\u20138.","journal-title":"Pediatr Crit Care Med"},{"issue":"8","key":"1477_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jcph.696","volume":"56","author":"T Liu","year":"2016","unstructured":"Liu T, et al. Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. J Clin Pharmacol. 2016;56(8):1009\u201318.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1477_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/psp4.12407","volume":"8","author":"T Liu","year":"2019","unstructured":"Liu T, et al. Could postnatal age\u2013related uridine diphosphate glucuronic acid be a rate-limiting factor in the metabolism of morphine during the first week of life? CPT Pharmacometrics Syst Pharmacol. 2019;8(7):469\u201377.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1477_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pan.13020","volume":"27","author":"JM Dawes","year":"2017","unstructured":"Dawes JM, et al. Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. Paediatr Anaesth. 2017;27(1):28\u201336.","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"1477_CR30","doi-asserted-by":"publisher","first-page":"E485","DOI":"10.1097\/CCM.0000000000003741","volume":"47","author":"AF Zuppa","year":"2019","unstructured":"Zuppa AF, et al. Morphine dose optimization in critically ill pediatric patients with acute respiratory failure: a population pharmacokinetic-pharmacogenomic study. Crit Care Med. 2019;47(6):E485\u201394.","journal-title":"Crit Care Med"},{"issue":"10","key":"1477_CR31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2217\/pgs.14.99","volume":"15","author":"R Venkatasubramanian","year":"2014","unstructured":"Venkatasubramanian R, et al. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014;15(10):1297\u2013309.","journal-title":"Pharmacogenomics"},{"key":"1477_CR32","doi-asserted-by":"crossref","unstructured":"Velez de Mendizabal N, et al. A compartmental analysis for morphine and its metabolites in young children after a single oral dose. Clin Pharmacokinet. 2015;54(10): 1083-1090.","DOI":"10.1007\/s40262-015-0256-4"},{"issue":"5","key":"1477_CR33","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/bja\/aen248","volume":"101","author":"KJS Anand","year":"2008","unstructured":"Anand KJS, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br JAnaesth. 2008;101(5):680\u20139.","journal-title":"Br JAnaesth."},{"key":"1477_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ejps.2016.06.026","volume":"92","author":"KR Knosgaard","year":"2016","unstructured":"Knosgaard KR, et al. Pharmacokinetic models of morphine and its metabolites in neonates: systematic comparisons of models from the literature, and development of a new meta-model. Eur J Pharm Sci. 2016;92:117\u201330.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"1477_CR35","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2165\/00003088-200948060-00003","volume":"48","author":"CAJ Knibbe","year":"2009","unstructured":"Knibbe CAJ, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet. 2009;48(6):371\u201385.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1477_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/bja\/aeh042","volume":"92","author":"NJ Bouwmeester","year":"2004","unstructured":"Bouwmeester NJ, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92(2):208\u201317.","journal-title":"Br J Anaesth"},{"issue":"5","key":"1477_CR37","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/cpt.1917","volume":"108","author":"LMA Favie","year":"2020","unstructured":"Favie LMA, et al. Prediction of drug exposure in critically ill encephalopathic neonates treated with therapeutic hypothermia based on a pooled population pharmacokinetic analysis of seven drugs and five metabolites. Clin Pharmacol Therap. 2020;108(5):1098\u2013106.","journal-title":"Clin Pharmacol Therap."},{"issue":"1","key":"1477_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1208\/s12248-015-9826-5","volume":"18","author":"MH Elkomy","year":"2016","unstructured":"Elkomy MH, et al. Pharmacokinetics of morphine and its metabolites in infants and young children after congenital heart surgery. AAPS J. 2016;18(1):124\u201333.","journal-title":"AAPS J"},{"issue":"10","key":"1477_CR39","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2217\/pgs.13.94","volume":"14","author":"T Fukuda","year":"2013","unstructured":"Fukuda T, et al. OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics. 2013;14(10):1141\u201351.","journal-title":"Pharmacogenomics"},{"issue":"4","key":"1477_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5055\/jom.2012.0119","volume":"8","author":"S Sadhasivam","year":"2012","unstructured":"Sadhasivam S, et al. Morphine clearance in children: Does race or genetics matter? J Opioid Manage. 2012;8(4):217\u201326.","journal-title":"J Opioid Manage."},{"key":"1477_CR41","unstructured":"Australian Medicines Handbook (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2024."},{"key":"1477_CR42","unstructured":"Australasian Neonatal Medicines Formulary (ANMF). Royal Hospital for Women, New South Wales. 2023."},{"issue":"4","key":"1477_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/jcpt.12152","volume":"39","author":"D Zhou","year":"2014","unstructured":"Zhou D, et al. Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam. J Clin Pharm Ther. 2014;39(4):404\u201310.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1477_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11011-011-9274-6","volume":"27","author":"S De Gregori","year":"2012","unstructured":"De Gregori S, et al. Morphine metabolism, transport and brain disposition. Metab Brain Dis. 2012;27(1):1\u20135.","journal-title":"Metab Brain Dis"},{"issue":"5","key":"1477_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","volume":"28","author":"M Dean","year":"2004","unstructured":"Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497\u2013504.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1477_CR46","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/bcp.14426","volume":"88","author":"T Mizuno","year":"2022","unstructured":"Mizuno T, et al. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient care. Br J Clin Pharmacol. 2022;88(4):1418\u201326.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1477_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/cpt.1684","volume":"107","author":"AA Vinks","year":"2020","unstructured":"Vinks AA, et al. Electronic health record-embedded decision support platform for morphine precision dosing in neonates. Clin Pharmacol Ther. 2020;107(1):186\u201394.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1477_CR48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40262-012-0006-9","volume":"51","author":"EH Krekels","year":"2012","unstructured":"Krekels EH, et al. Prediction of morphine clearance in the paediatric population: how accurate are the available pharmacokinetic models? Clin Pharmacokinet. 2012;51(11):695\u2013709.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1477_CR49","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11095-010-0333-1","volume":"28","author":"EHJ Krekels","year":"2011","unstructured":"Krekels EHJ, et al. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797\u2013811.","journal-title":"Pharm Res"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01477-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01477-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01477-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:02:11Z","timestamp":1749668531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01477-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1477"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01477-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"5 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"MS, SS, MF and IS conceived the article and determined the study design. MS and NK participated in article screening, and collection of data. MS drafted the manuscript and analysed the results. All authors contributed to critical review of the manuscript draft and approved the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}